EuroBiotech: More Articles of Note

Newspapers

> Silenseed is trying to raise $10 million to fund a phase 2 pancreatic cancer trial. The trial will assess the efficacy of the Israeli biotech’s KRAS-targeting siRNA. Silenseed tried to raise money via a Nasdaq IPO in 2014 but aborted its attempt the following year. The company is also planning to combine its siRNA with an immunotherapy. Statement   

> Kamada priced a stock offering expected to gross about $15 million. The Israeli biotech plans to use the money to fund late-phase clinical trials. Release 

> ITeos Therapeutics secured a €7.5 million grant. The money equips iTeos to move its adenosine receptor A2A antagonist into the clinic. A trial of the cancer candidate is due to start in Belgium next year. Statement  

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> The United Kingdom outlined plans to create a National investment Fund. The vehicle is intended to ensure startups in life sciences and other industries have the cash they need to blossom, regardless of whether the U.K. cuts its ties to the European Investment Fund after Brexit. Release  

> Compugen named Paul Sekhri as its chairman. The appointment gives Compugen access to the experience and network of a life sciences veteran who has held senior positions at companies including Novartis, Sanofi and Teva. Statement

> Valneva appointed Wolfgang Bender, M.D., Ph.D., as its CMO. Bender joins Valneva after holding leadership positions in the medical affairs teams at Takeda and Novartis’ vaccine units. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.